Key result
Subcutaneous reviparin given once daily reduced the risk of deep-vein thrombosis compared to placebo (9% vs 19%; OR 0.45, 95% CI 0.24-0.82) in patients with leg injury requiring immobilization.
Why the study?
Does subcutaneous reviparin prevent deep-vein thrombosis in patients requiring prolonged leg immobilization after injury?
RCT (n=440)
Double-blind
randomly assigned
Does subcutaneous reviparin prevent deep-vein thrombosis in patients requiring prolonged leg immobilization after injury?
Odds Ratio: 0.45 (95% CI 0.24–0.82)
Absolute Event Rate: 9% vs 19%
Prophylactic use of the low-molecular-weight heparin reviparin significantly reduces the incidence of deep-vein thrombosis in patients requiring prolonged leg immobilization after injury.
Authors
No takes yet. Share an insight, caveat, or question.
Reviparin prophylaxis may be considered after leg immobilization; extends LMWH evidence to fracture and tendon-rupture patients.
Lassen et al. (2002) conducted an RCT in Leg injury requiring immobilization (n=440). Reviparin vs. Placebo was evaluated on Deep-vein thrombosis (OR 0.45, 95% CI 0.24 to 0.82). Subcutaneous reviparin given once daily reduced the risk of deep-vein thrombosis compared to placebo (9% vs 19%; OR 0.45, 95% CI 0.24-0.82) in patients with leg injury requiring immobilization.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: